CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands
- PMID: 28025495
- PMCID: PMC5297650
- DOI: 10.3390/ijms18010015
CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands
Abstract
The peroxisome proliferator-activated receptor γ (PPARγ) ligands are important therapeutic drugs for the treatment of type 2 diabetes, obesity and cardiovascular diseases. In particular, partial agonists and non-agonists are interesting targets to reduce glucose levels, presenting few side effects in comparison to full agonists. In this work, we present a set of CHARMM-based parameters of a molecular mechanics force field for two PPARγ ligands, GQ16 and SR1664. GQ16 belongs to the thiazolidinedione class of drugs and it is a PPARγ partial agonist that has been shown to promote the "browning" of white adipose tissue. SR1664 is the precursor of the PPARγ non-agonist class of ligands that activates PPARγ in a non-classical manner. Here, we use quantum chemical calculations consistent with the CHARMM protocol to obtain bonded and non-bonded parameters, including partial atomic charges and effective torsion potentials for both molecules. The newly parameterized models were evaluated by examining the behavior of GQ16 and SR1664 free in water and bound to the ligand binding pocket of PPARγ using molecular dynamics simulations. The potential parameters derived here are readily transferable to a variety of pharmaceutical compounds and similar PPARγ ligands.
Keywords: CHARMM parameters; GQ16; PPARγ ligands; SR1664; molecular dynamics; nuclear receptor.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.J Biol Chem. 2014 Sep 19;289(38):26618-26629. doi: 10.1074/jbc.M114.566794. Epub 2014 Aug 6. J Biol Chem. 2014. PMID: 25100724 Free PMC article.
-
Rational design of thiazolidine-4-one-gallic acid hybrid derivatives as selective partial PPARγ modulators: an in-silico approach for type 2 diabetes treatment.J Biomol Struct Dyn. 2025 Feb;43(2):694-708. doi: 10.1080/07391102.2023.2283161. Epub 2023 Nov 24. J Biomol Struct Dyn. 2025. PMID: 37997952
-
Unique Interactome Network Signatures for Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Modulation by Functional Selective Ligands.Mol Cell Proteomics. 2017 Dec;16(12):2098-2110. doi: 10.1074/mcp.RA117.000308. Epub 2017 Sep 29. Mol Cell Proteomics. 2017. PMID: 28972081 Free PMC article.
-
Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.Trends Pharmacol Sci. 2015 Oct;36(10):688-704. doi: 10.1016/j.tips.2015.06.010. Trends Pharmacol Sci. 2015. PMID: 26435213 Review.
-
Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.Molecules. 2018 Sep 22;23(10):2431. doi: 10.3390/molecules23102431. Molecules. 2018. PMID: 30248999 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources